The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.

ABSTRACT:

Purpose of review

Studies show that inhibitors of Bruton's tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summarize recent data supporting the use of these drugs as novel therapies in various allergic disorders.

Recent findings

Recent studies have shown that BTKis can prevent IgE-mediated degranulation and cytokine production in primary human mast cells and basophils. Two oral doses of the second-generation BTKi acalabrutinib can completely prevent moderate passive systemic anaphylaxis in humanized mice and even protect against death during severe anaphylaxis. Furthermore, two doses of ibruti

SUBMITTER: Dispenza MC 

PROVIDER: S-EPMC8050815 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature